18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Impact of FHIT loss on the translation of cancer-associated mRNAs

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          FHIT is a genome caretaker/tumor suppressor that is silenced in >50% of cancers. Although it was identified more than 20 years ago, questions remain as to how FHIT loss contributes to cancer, and conversely, how FHIT acts to maintain genome integrity and suppress malignancy. Fhit belongs to the histidine triad family of enzymes that catalyze the degradation of nucleoside 5′,5′-triphosphates, including the m 7GpppN ‘caps’ that are generated when mRNAs undergo 3′-5′ decay. This raised the possibility that Fhit loss might affect changes in the translation of cancer-associated mRNAs, possibly as a consequence of increased intracellular concentrations of these molecules.

          Results

          Ribosome profiling identified several hundred mRNAs for which coding region ribosome occupancy changed as a function of Fhit expression. While many of these changes could be explained by changes in mRNA steady-state, a subset of these showed changes in translation efficiency as a function of Fhit expression. The onset of malignancy has been linked to changes in 5’-UTR ribosome occupancy and this analysis also identified ribosome binding to 5′-untranslated regions (UTRs) of a number of cancer-associated mRNAs. 5’-UTR ribosome occupancy of these mRNAs differed between Fhit-negative and Fhit-positive cells, and in some cases these differences correlated with differences in coding region ribosome occupancy.

          Conclusions

          In summary, these findings show Fhit expression impacts the translation of a number of cancer associated genes, and they support the hypothesis that Fhit’s genome protective/tumor suppressor function is associated with post-transcriptional changes in expression of genes whose dysregulation contributes to malignancy.

          Electronic supplementary material

          The online version of this article (10.1186/s12943-017-0749-x) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: not found

          Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions.

          DNA damage checkpoint genes, such as p53, are frequently mutated in human cancer, but the selective pressure for their inactivation remains elusive. We analysed a panel of human lung hyperplasias, all of which retained wild-type p53 genes and had no signs of gross chromosomal instability, and found signs of a DNA damage response, including histone H2AX and Chk2 phosphorylation, p53 accumulation, focal staining of p53 binding protein 1 (53BP1) and apoptosis. Progression to carcinoma was associated with p53 or 53BP1 inactivation and decreased apoptosis. A DNA damage response was also observed in dysplastic nevi and in human skin xenografts, in which hyperplasia was induced by overexpression of growth factors. Both lung and experimentally-induced skin hyperplasias showed allelic imbalance at loci that are prone to DNA double-strand break formation when DNA replication is compromised (common fragile sites). We propose that, from its earliest stages, cancer development is associated with DNA replication stress, which leads to DNA double-strand breaks, genomic instability and selective pressure for p53 mutations.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Translational control by 5'-untranslated regions of eukaryotic mRNAs.

            The eukaryotic 5' untranslated region (UTR) is critical for ribosome recruitment to the messenger RNA (mRNA) and start codon choice and plays a major role in the control of translation efficiency and shaping the cellular proteome. The ribosomal initiation complex is assembled on the mRNA via a cap-dependent or cap-independent mechanism. We describe various mechanisms controlling ribosome scanning and initiation codon selection by 5' upstream open reading frames, translation initiation factors, and primary and secondary structures of the 5'UTR, including particular sequence motifs. We also discuss translational control via phosphorylation of eukaryotic initiation factor 2, which is implicated in learning and memory, neurodegenerative diseases, and cancer.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Signatures of mutation and selection in the cancer genome.

              The cancer genome is moulded by the dual processes of somatic mutation and selection. Homozygous deletions in cancer genomes occur over recessive cancer genes, where they can confer selective growth advantage, and over fragile sites, where they are thought to reflect an increased local rate of DNA breakage. However, most homozygous deletions in cancer genomes are unexplained. Here we identified 2,428 somatic homozygous deletions in 746 cancer cell lines. These overlie 11% of protein-coding genes that, therefore, are not mandatory for survival of human cells. We derived structural signatures that distinguish between homozygous deletions over recessive cancer genes and fragile sites. Application to clusters of unexplained homozygous deletions suggests that many are in regions of inherent fragility, whereas a small subset overlies recessive cancer genes. The results illustrate how structural signatures can be used to distinguish between the influences of mutation and selection in cancer genomes. The extensive copy number, genotyping, sequence and expression data available for this large series of publicly available cancer cell lines renders them informative reagents for future studies of cancer biology and drug discovery.
                Bookmark

                Author and article information

                Contributors
                dlkiss@houstonmethodist.org
                baez.15@osu.edu
                kay.huebner@osumc.edu
                bundschuh.2@osu.edu
                schoenberg.3@osu.edu
                Journal
                Mol Cancer
                Mol. Cancer
                Molecular Cancer
                BioMed Central (London )
                1476-4598
                28 December 2017
                28 December 2017
                2017
                : 16
                : 179
                Affiliations
                [1 ]ISNI 0000 0001 2285 7943, GRID grid.261331.4, Center for RNA Biology, , The Ohio State University, ; Columbus, OH 43210 USA
                [2 ]ISNI 0000 0001 2285 7943, GRID grid.261331.4, Comprehensive Cancer Center, , The Ohio State University, ; Columbus, OH 43210 USA
                [3 ]ISNI 0000 0001 2285 7943, GRID grid.261331.4, Department of Biological Chemistry and Pharmacology, , The Ohio State University, ; Columbus, OH 43210 USA
                [4 ]ISNI 0000 0001 2285 7943, GRID grid.261331.4, Department of Physics, , The Ohio State University, ; Columbus, OH 43210 USA
                [5 ]ISNI 0000 0001 2285 7943, GRID grid.261331.4, Department of Cancer Biology and Genetics, , The Ohio State University, ; Columbus, OH 43210 USA
                [6 ]ISNI 0000 0001 2285 7943, GRID grid.261331.4, Department of Chemistry & Biochemistry, , The Ohio State University, ; Columbus, OH 43210 USA
                [7 ]ISNI 0000 0001 2285 7943, GRID grid.261331.4, Division of Hematology, Department of Internal Medicine, , The Ohio State University, ; Columbus, OH 43210 USA
                [8 ]ISNI 0000 0004 0445 0041, GRID grid.63368.38, Biomarker Research Program, , Houston Methodist Research Institute, ; Houston, TX 77030 USA
                Article
                749
                10.1186/s12943-017-0749-x
                5745650
                29282095
                fa9a5cad-9ea7-4018-94e6-6e3d4855cd85
                © The Author(s). 2017

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 9 October 2017
                : 10 December 2017
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100000057, National Institute of General Medical Sciences;
                Award ID: GM084177
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100000054, National Cancer Institute;
                Award ID: CA0093338
                Funded by: FundRef http://dx.doi.org/10.13039/100000001, National Science Foundation;
                Award ID: DMR-1410172
                Award Recipient :
                Funded by: Pelotonia
                Categories
                Research
                Custom metadata
                © The Author(s) 2017

                Oncology & Radiotherapy
                fhit,translational control,ribosome profiling,scavenger decapping,gene expression

                Comments

                Comment on this article